Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety Follow-up Platform Study for Pulmonary Hypertension Interventions
2021-002297-11Phase 3Active
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of macitentan and tadalafil in pulmonary hypertension (PH) (2 arms), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoints: Treatment-emergent adverse events, Treatment-emergent AEs leading to discontinuation and 1 more. Started Dec 2021; status: active.
02
Drugs
macitentantadalafil
03
Conditions
pulmonary hypertension (PH)
Beyond the preview
Go deeper on 2021-002297-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002297-11.